Conversion calendar in hand: management narrates the coming year as dated deliveries of business already secured
The model's full reasoning — Q4 2022 call → NOThe question asks whether management lays out a timetable of specific conversions—identified pieces of business already secured or in motion, each attached to an approximate time frame—so the forward story reads as a schedule of things turning on. Let me examine the transcript for evidence: 1. MRD business: clonoSEQ clinical volumes grew 51%, launched in DLBCL, signed Epic agreement. Management says DLBCL launch and Epic integration are "back half drivers" for 2023. They expect DLBCL to be a meaningful contributor in the second half of 2023. Epic integration expected in back half of year. 2. Genentech IND acceptance: "the IND acceptance for immune medicine, obviously, a big swing factor toward the end of the year. And that's the biggest swing factor in the fourth quarter." They recognized $7 million of the $10 million upfront on acceptance of that milestone. This is in guidance. 3. MRD milestones: "we anticipate MRD milestones in the mid to high single digit millions" and "milestones in both immune medicine and MRD, which were expected by year-end." 4. Revenue guidance: back half weighted, Q1 lowest. Now, are these "already real" items? The DLBCL launch happened (launched at ASH in December). Epic agreement signed. Genentech IND acceptance is pending—it's a milestone that hasn't been achieved yet, it's expected by year-end. That's contingent on FDA acceptance, which is not yet secured. The MRD milestones—are they secured? They say "we anticipate MRD milestones in the mid to high single digit millions" and "we've got roughly 370 million future milestones... we risk adjust those in our guidance with about a 30% to 50% probability of success." So these are risk-adjusted, not secured. The DLBCL launch and Epic integration are real (launched, signed), and they're expected to contribute in the back half. But are they "already real" in the sense of secured business? The launch is done, the integration is signed. But the contribution depends on adoption, which is still being pursued. The Genentech IND is explicitly contingent on FDA acceptance—that's an approval not yet made. So that doesn't count. The MRD milestones are risk-adjusted with 30-50% probability—those are not secured. So what's left? DLBCL launch (done) and Epic integration (signed). These are real items with timing (back half).
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| ESEA | Euroseas Ltd. | Q4 2022 | 2023-02-15 | C+ |
| SOL | ReneSola Ltd | Q3 2022 | 2022-12-01 | C+ |
| FLL | Full House Resorts, Inc. | Q3 2022 | 2022-11-07 | B |
| FAT | FAT Brands Inc. | Q4 2021 | 2022-03-21 | F |
| CPK | Chesapeake Utilities Corporation | Q3 2017 | 2017-11-10 | A |
| ESE | ESCO Technologies Inc. | Q2 2016 | 2016-05-03 | A |
CPK · Q3 2017 → YESThe question is about whether management lays out a timetable of specific conversions for the next four or so quarters, with already secured business and approximate time frames.
SOL · Q3 2022 → YESThe question is about whether management lays out a timetable of specific conversions for the next four or so quarters, with already secured items and approximate time frames.
FLL · Q3 2022 → YESThe question is about whether management lays out a timetable of specific conversions for the next four or so quarters, with already secured items and approximate time frames.